Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins ? significance for the patient

Hartinger, C.G.; Hann, S.; Koellensperger, G.; Sulyok, M.; Grössl, Michael; Timerbaev, A.R.; Rudnev, A.V.; Stingeder, G.; Keppler, B.K. (2005). Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins ? significance for the patient. International journal of clinical pharmacology and therapeutics, 43(12), pp. 583-585. Dustri-Verlag 10.5414/CPP43583

Full text not available from this repository. (Request a copy)

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension
UniBE Contributor:	Grössl, Michael
Subjects:	600 Technology > 610 Medicine & health
ISSN:	0946-1965
Publisher:	Dustri-Verlag
Language:	English
Submitter:	Michael Grössl
Date Deposited:	04 Oct 2019 15:17
Last Modified:	05 Dec 2022 15:11
Publisher DOI:	10.5414/CPP43583
PubMed ID:	16372526
URI:	https://boris.unibe.ch/id/eprint/112165